1/6
CHC Pharmacology manual
Acetaminophen (Tylenol, Paracetamol)
Class: Analgesic, Antipyretic
MOA: Acetaminophen primarily inhibits prostaglandin production in the central nervous system (brain and spinal cord), which reduces pain signaling. It also acts on the hypothalamus, the brain's temperature-regulating center, to lower fever.
Indications:
• Mild to moderate pain
• Severe pain when other analgesics are contraindicated or deferred
• Pain or myalgias associated with fever
• Adjunct with opioid analgesics for severe pain (hospital use)
Contraindications:
• Acute ethanol intoxication
• Acute acetaminophen overdose
• Known ingestion of 4 g acetaminophen in the last 24 hrs
• History of acute or severe liver disease
Precautions:
• May cause severe liver impairments, especially if given in large doses or too quickly Significant adverse/side effects:
• Allergic/anaphylactic reactions
• Muscle pain or cramps (Tetany), twitching
• Skin rash
• Pruritus- intense, uncomfortable sensation of itchy skin
• N/V • Nephrotoxicity
• Abdominal pain
Dosage: Adult: 1 g IV/IO infusion (IVPB) over 15 mins. Single dose only
Peds (2-14 yrs): 15 mg/kg to a max of 1 g over 15 mins. Single dose only
Activated Charcoal (Acta-Char)
Class: Adsorbent, gastric decontaminant
MOA: Activated charcoal binds to certain toxins and medications in the gastrointestinal tract, preventing them from being absorbed into the bloodstream. The charcoal and bound toxins are then eliminated through the feces.
Indication(s):
• Toxic ingestion within 1 hour of EMS contact
Contraindications:
• PO dose- Altered mental status without a protected airway (i.e., not intubated, can be given OG or NG)
• Due to the increased risk of aspiration without benefit, activated charcoal should not be administered following the ingestion of a substance known not to be absorbed (electrolytes, iron, lithium, heavy metals, acids or bases, alcohols, cyanide, most common solvents, and most water-insoluble compounds such as hydrocarbons (petroleum distillates)).
• Corrosive ingestion (Activated charcoal obscures endoscopy, which is performed in such ingestions) unless there are life-threatening co-ingestants that AC adsorbs
Precautions:
• Administration of Activated Charcoal increases the risk for aspiration.
• Must shake vigorously prior to administration Significant adverse/side effects:
• Nausea/vomiting • Intestinal obstruction (associated with the administration of multiple doses)
Dosage: Adult- 1 g/kg PO (50 g average dose)
Peds- 1 g/kg PO
Adeosine (Adenocard)
Class: Antidysrhythmic, Endogenous nucleoside
MOA: Adenosine temporarily slows electrical conduction through the AV node and increases its refractory period, interrupting reentrant electrical circuits that cause certain supraventricular tachycardias (SVT), allowing normal sinus rhythm to return.
Indication(s):
• Narrow complex tachycardia (SVT/PSVT)
• SVT with aberrancy (looks like VTAC)
Contraindications:
• Atrial fibrillation associated with WPW Syndrome
• Hx of Sick Sinus Syndrome
Precautions:
• The administration of adenosine to a patient with atrial fibrillation and Wolff-Parkinson- White (WPW) Syndrome may result in ventricular fibrillation.
• Adenosine may induce airway hyperresponsiveness and should be used cautiously in patients with a history of reactive airway disease (asthma).
• Patients who are status post cardiac transplant may demonstrate increased sensitivity to adenosine.
• Cannulate the largest vein possible to facilitate rapid flush following administration
Significant adverse/side effects:
• Headache
• Chest pain
• Flushing
• Dyspnea/bronchoconstriction
• Bradycardia
• AV block
• Sinus pause/asystole/PVCs
Dosage: Adult: 6 mg rapid IVP/IO followed by 20 ml flush. May repeat with 12 mg twice after 1-2 mins each Peds: 0.1 mg/kg rapid IVP/IO followed by 5-10 ml flush (depends on patient size) May repeat with 0.2 mg/kg twice after 1-2 mins
Notes:
• For a poorly perfusing, symptomatic patient, consider synchronized cardioversion prior to Adenosine.
• REMSA starts at 12 mg and requires a BHO for repeat, the 12 mg can be mixed with the flush fluid for a single administration.
Albuterol (Ventolin, Proventil)
Class: Sympathomimetic Bronchodilator, Beta Adrenergic agonist (B2 selective)
MOA: Albuterol stimulates beta-2 adrenergic receptors, increasing cAMP inside smooth muscle cells. This reduces calcium-dependent muscle contraction, causing the bronchial smooth muscles to relax and the airways to dilate, making breathing easier.
Indications:
• Bronchospasms associated with asthma/reactive airway
• Toxic gas inhalation/OD
• Allergic reactions/anaphylaxis
• COPD
• Drowning
• Hyperkalemia (crush injury)
Contraindications:
• None
Precautions:
• Use with caution in patients with myocardial ischemia.
• Paradoxical bronchospasm may occur in a small percentage of patients, possibly due to other compounds in the albuterol preparation. If suspected (significantly increased and severe bronchospasm following administration), discontinue use and avoid levalbuterol.
• Beta-blocker medications and albuterol inhibit each other.
Significant adverse/side effects:
• Tachycardia
• Palpitations/cardiac ectopy
• Tremors
• Headache
• Nausea/vomiting
• Coughing
Dosage: Adult and Peds: 2.5 mg in 3 mL NS nebulized. Repeats are protocol-dependent
Amiodarone (Cardarone)
Class: Antidysrhythmic
MOA: Amiodarone primarily blocks potassium channels in cardiac cells, slowing repolarization and prolonging the refractory period. This makes cardiac cells take longer to recover before they can fire again, helping suppress abnormal electrical activity and interrupt reentrant circuits that cause dysrhythmias.
Indications:
• Ventricular tachycardia (VT/VTAC)
• Ventricular fibrillation (VF/VFIB)
• Wide complex tachycardias
• Symptomatic PVCs
Contraindications:
• Iodine hypersensitivity
• Bradycardia
• AV block >1 degree in the absence of a pacemaker
Precautions:
• Due to its vasodilatory properties, amiodarone administration in cardiac arrest should be preceded by a vasopressor (i.e., epinephrine).
• Amiodarone should not be used in individuals with polymorphic VT associated with a prolonged QT interval.
• Amiodarone for long-term infusion should only be diluted with D5W and given with an in-line filter.
• Amiodarone used with beta or calcium-blocking agents may increase the risk of hypotension and bradycardia.
Significant adverse/side effects:
• Hypotension
• Bradycardia
• AV block
• Torsades de pointes
• Congestive heart failure
• Phlebitis
Dosage: Adult:
• Arrest: 300 mg IVP/IO followed by 10-20 mL NS flush. Second dose: 150 mg IVP/IO followed by 10-20 mL NS flush in 3-5 mins if no conversion
• Wide-complex tachycardia/symptomatic PVCs: 150 mg slow INFUSION/IVPB/IO over 10-15 mins. Max dose 450 mg
• ACLS/REMSA bolus infusion: 150 mg INFUSION/IVPB over 10 mins (15 mg/min). Repeat 150 mg every 10 mins as needed (max 450 mg)
• Slow infusion (ACLS): 360 mg INFUSION/IVPB over 6 hrs (1 mg/min)
• Maintenance infusion (ACLS): 540 mg INFUSION/IVPB over 18 hrs (0.5 mg/min)
Peds (PALS dosing):
• VT/VF arrest: 5 mg/kg IVP/IO followed by a flush. Max dose 15 mg/kg
• Tachydysrhythmias: 5 mg/kg INFUSION/IVPB/IO over 20-60 mins. Max dose 15 mg/kg
Notes:
• The conventional IV preparation contains polysorbate 80 and benzyl alcohol, which are believed to contribute to bradycardia and hypotension. A newer formulation (Nexterone) does not contain these preservatives.
• Amiodarone infusions should be mixed in D5W. In cardiac arrest, the bolus dose may be diluted in 20-50 mL NS or D5W.
• No amiodarone in ICEMA protocols.
• REMSA dosing: see calculation chart for pediatric doses.
• The total maximum cumulative 24-hour dose of amiodarone is 2.2 g
Aspirin (acetylsalicylic acid, ASA)
Class: Platelet Aggregate Inhibitor; Analgesic; Antipyretic; Non-steroidal Anti inflammatory (NSAID)
MOA: Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, decreasing the production of thromboxane A2 (TXA2) and prostaglandins (PGE2). This prevents platelets from clumping together, reduces pain and inflammation, and lowers fever.
Indications:
• Acute coronary syndrome (think STEMI or NSTEMI)
• Chest pain/discomfort believed to be of cardiac etiology (angina)
• Afib/Aflutter
Contraindications:
• Peptic ulcer disease (relative for cardiac indications)
• Pediatric or adolescent patient
• Not used for pain relief in the prehospital setting!
Precautions:
• ASA is contraindicated in pediatric or adolescent patients due to concern for Reye's syndrome (Reye's syndrome is characterized by CNS damage, liver injury, and hypoglycemia).
Significant adverse/side effects:
• Gastritis
• Nausea/vomiting
• Upper GI bleeding
• Increased bleeding
Dosage: Adult: 324-325 mg PO
Note: One adult tab = 325 mg; 4 low dose (81 mg) tabs = 324 mg.
Atropine Sulfate
Class: Anticholinergic; Antimuscarinic; Parasympatholytic
MOA: Atropine competitively blocks acetylcholine (ACh) at muscarinic receptors, inhibiting parasympathetic activity. This removes the vagus nerve's slowing effect on the heart, increasing heart rate and AV nodal conduction. It also decreases secretions, causes bronchodilation, and reduces gastrointestinal and bladder motility.
Indications:
Symptomatic (sinus) bradycardia
Organophosphate/nerve agent toxicity
Prior to PAI/RSI in pediatrics (national curriculum)
Contraindications:
- Glaucoma (relative contraindication in life-threatening bradycardia)
Precautions:
Use cautiously in patients with myocardial ischemia or hypoxia because increased heart rate raises myocardial oxygen demand and may worsen ischemia.
Atropine administration should not delay external pacing in patients with poor perfusion.
May be ineffective in second-degree AV block Type II (Mobitz II) and new third-degree AV block with wide QRS complexes due to infranodal conduction abnormalities.
Transplanted hearts are denervated and generally do not respond to atropine.
Significant adverse/side effects:
Tachycardia (may worsen myocardial ischemia)
Blurred vision (high doses)
Urinary retention
Dry skin
Confusion (high doses)
Acute narrow-angle glaucoma
Dosage: Adult:
- Bradycardia: 1 mg IVP/IO
May repeat every 3–5 minutes to a maximum of 3 mg or 0.04 mg/kg.
- Pesticides/Nerve toxins: 2 mg IVP/IO/IM
May repeat every 5 minutes until the patient is asymptomatic or shows signs of atropinization.
Dosage: Pediatric:
- PAI/RSI: 0.01–0.02 mg/kg IVP/IO
Minimum single dose: 0.1 mg. Maximum single dose: 1 mg.
- All Cardiac: 0.02 mg/kg IVP/IO
Minimum single dose: 0.1 mg. Maximum single dose: 1 mg. May repeat once after 5 minutes.
- Pesticides/Nerve toxins (under 14 years): 0.05 mg/kg IVP/IO/IM
May repeat every 5 minutes until asymptomatic or signs of atropinization.
- Pesticides/Nerve toxins (over 14 years): 2 mg IVP/IO/IM
May repeat up to 2 mg every 5 minutes until asymptomatic or signs of atropinization.
Notes:
Signs of atropinization: Blind as a bat, mad as a hatter, red as a beet, dry as a bone, hot as hell.
REMSA uses a maximum of 3 mg. ICEMA and ACLS use a maximum of 3 mg or 0.04 mg/kg for adult bradycardia, as stated in your manual.
May be used to manage excessive salivation associated with ketamine administration in the hospital setting.
Caution: Small doses or slow administration of atropine may cause paradoxical bradycardia.
Organophosphate poisoning: Atropine blocks the muscarinic effects of excess acetylcholine but does not reactivate acetylcholinesterase or reverse nicotinic effects.